Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "100 Years of BCG Immunization: Past, Present and Future"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (10 April 2022) | Viewed by 17539
Special Issue Editors
Interests: vaccines; adjuvants; infectious diseases; mucosal immunity; cytokines
Interests: innate immunity; inflammation; innate memory; adjuvants; immunosafety
Special Issues, Collections and Topics in MDPI journals
Interests: vaccine-induced immunity; vaccine development; recombinant BCG
E-Mail Website1 Website2
2. Max Planck Institute for Biophysical Chemistry, Göttingen, Germany
3. Faculty Fellow of the Hagler Institute for Advanced Study, Texas A&M University, College Station, TX, USA
Interests: microbiology; tuberculosis; immunology; biology; infection; vaccinology; biosignatures; recombinant BCG
Special Issue Information
The tuberculosis vaccine Bacille Calmette–Guérin (BCG) has been available for 100 years, but tuberculosis remains a major health threat. BCG vaccine efficacy has been demonstrated when administered to children below 5 years of age, against pulmonary, meningeal, and disseminated tuberculosis (TB), while its efficacy in adults has been shown to vary widely in different epidemiological conditions, and its capacity to prevent infection is still debated. BCG efficacy against leprosy is higher but likewise variable. An additional concern is the increasing appearance of multiple antibiotic-resistant variants of Mycobacterium tuberculosis and Mycobacterium leprae, which urgently calls for effective preventive measures. Thus, better vaccines are needed. Several candidates have been developed in recent decades employing molecular technologies to obtain antigen/adjuvant subunit vaccines, viral vectored vaccines, and whole cell mycobacterial vaccines that come as live recombinant vaccines. In the century of BCG immunization, it has become clear that the administration of live attenuated BCG can have other effects in addition to inducing specific immunity against M. tuberculosis. BCG is also considered the gold standard for primary therapy of carcinoma in situ of the bladder, most likely for its capacity to activate the host innate/inflammatory response against the tumor. Despite its limitations, to date, BCG has not been surpassed by any other treatment. Along the same line, several other interesting findings suggest that BCG can have beneficial non-specific effects (NSE), from controlling hyperglycemia in type 1 diabetes to decreasing childhood mortality. The BCG NSE have received a lot of interest recently in the attempt to find effective treatments for COVID-19. The possibility is currently being investigated that BCG could prime the innate immune system of vaccinees and generate an innate immune memory able to afford a better, pathogen-agnostic antimicrobial resistance. Additionally, the capacity of BCG to interfere with the cellular energy metabolism and epigenetic reprogramming of metabolic, immune, and inflammatory responses could be exploited for treating a variety of non-infectious diseases, in particular autoimmune and chronic inflammatory conditions such as allergic asthma, insulin-dependent diabetes, and multiple sclerosis
Dr. Aldo Tagliabue
Dr. Diana Boraschi
Dr. Luciana C. C. Leite
Prof. Dr. Stefan H. E. Kaufmann
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- TB vaccines
- bladder carcinoma
- innate memory